Could there be more accelerated approvals for drugs outside of oncology? Former FDA rheumatology official Jeffrey Siegel, now a Genentech exec, talks to “The Pink Sheet” journalist Emily Hayes about how his company is targeting areas of unmet need and muses on possibilities for faster approvals in his field. Recorded onsite at the American College of Rheumatology meeting November 10, 2015, San Francisco, CA.
